Table 2 Baseline and > 10-year demographic, clinical, and disease characteristics of 233 patients with and without the aggravation of VS at > 10-year follow-up.
Patients with VS aggravation | Patients without VS aggravation | p | |
|---|---|---|---|
(n = 70) | (n = 163) | ||
Age, mean ± SD years | 58.6 ± 9.4 | 58.7 ± 9.8 | 0.918 |
<55 years, n (%) | 21 (30.0) | 56 (34.4) | 0.806 |
55–64 years, n (%) | 27 (38.6) | 58 (35.6) | |
≥65 years, n (%) | 22 (31.4) | 49 (30.1) | |
Male sex, n (%) | 5 (7.1) | 29 (17.8) | 0.035† |
RA duration, mean ± SD years | 16.3 ± 10.1 | 12.1 ± 10.8 | 0.010‡ |
≥5 years, n (%) | 65 (92.9) | 119 (73.0) | < 0.001‡ |
CRP, mean ± SD mg/dL at baseline | 2.7 ± 2.9 | 2.0 ± 2.7 | 0.052 |
≥3.8 mg/dL, n (%) | 20 (28.6) | 23 (14.1) | 0.009‡ |
>1.0 mg/dL, n (%) | 43 (61.4) | 93 (57.1) | 0.535 |
CRP, mean ± SD mg/dL at > 10-year follow-up | 2.0 ± 1.7 | 1.6 ± 3.2 | 0.314 |
≥3.8 mg/dL, n (%) | 12 (17.1) | 12 (7.4) | 0.024† |
>1.0 mg/dL, n (%) | 47 (67.1) | 72 (44.2) | 0.001‡ |
RF positive, n (%) | 59 (84.3) | 132 (81.0) | 0.548 |
Previous joint surgery, n (%) | 47 (67.1) | 66 (40.5) | < 0.001‡ |
Treatments | |||
Corticosteroids, n (%) | 54 (77.1) | 96 (58.9) | 0.008‡ |
MTX, n (%) | 35 (50.0) | 63 (38.7) | 0.108 |
Other DMARDs, n (%) | 33 (47.1) | 90 (55.2) | 0.258 |
Biological agents, n (%) | 8 (11.4) | 11 (6.7) | 0.231 |
Steinbrocker stages and mutilating changes | |||
Stages I–II, n (%) | 6 (8.6) | 38 (23.3) | < 0.001‡ |
Stages III–IV, n (%) | 49 (70.0) | 118 (72.4) | |
Mutilating changes, n (%) | 15 (21.4) | 7 (4.3) | |
C2–C7 angle | 11.2 ± 14.9 | 13.4 ± 13.0 | 0.261 |
